Skip to main content

Healthcare- and pharma-economic models in support of the International Consortium for Personalised Medicine

Objective

HEcoPerMed responds to the demand for economic models that evaluate treatments made possible through innovations in personalised medicine and seeks to identify funding and reimbursement mechanisms that provide financial incentives for the rapid development and uptake of such innovations. HEcoPerMed goes beyond current assessment and payment models in order to serve the requirements of personalised medicine for more compre-hensive cost-effectiveness estimates that incorporate patient and societal perspectives and enhance sustainable affordability of cutting-edge health innovations. HEcoPerMed will provide an overview of and guidance on high-quality methodological approaches for model-based economic evaluations. In three case studies, HEcoPerMedwill apply state-of-the art economic modelling to demonstrate practical and methodological issues in evaluating personalised medicine innovations. The project team will also study existing shortcomings in stimulating the adoption of personalised medicine and pro-pose financial agreements that accelerate its diffusion in European health systems. HEcoPerMed will construct future scenarios, considering the trends and drivers as well as challenges and benefits of personalised medicine for the European social model of care and its financial viability. For a better financial integration of personalised medicine and new economic models, the project team will develop appropriate diffusion and communication strategies to be in direct contact with experts and a wide variety of stakeholders, taking their needs into account while offering new solutions for the players within the European health systems. These comprehensive measures will fill a gap identified by the ICPerMed to support their efforts in the promotion of personalised medicine in Europe and beyond. The project will support health care decision makers to manage their budgets while providing the best possible care for patients in the field of personalised medicine.

Call for proposal

H2020-SC1-2018-Single-Stage-RTD
See other projects for this call

Funding Scheme

CSA - Coordination and support action

Coordinator

AIT AUSTRIAN INSTITUTE OF TECHNOLOGY GMBH
Address
Giefinggasse 4
1210 Wien
Austria
Activity type
Research Organisations
EU contribution
€ 312 500

Participants (4)

DEUTSCHES ZENTRUM FUER LUFT - UND RAUMFAHRT EV
Germany
EU contribution
€ 700 937,50
Address
Linder Hoehe
51147 Koeln
Activity type
Research Organisations
INSTITUTE FOR MEDICAL TECHNOLOGY ASSESSMENT BV
Netherlands
EU contribution
€ 376 250
Address
Burgemeester Oudlaan 50
3062PA Rotterdam
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
SYREON KUTATO INTEZET KORLATOLT FELELOSSEGU TARSASAG
Hungary
EU contribution
€ 225 000
Address
Mexikoi Ut 65/A
1142 Budapest
Activity type
Private for-profit entities (excluding Higher or Secondary Education Establishments)
THE CHANCELLOR, MASTERS AND SCHOLARS OF THE UNIVERSITY OF OXFORD
United Kingdom
EU contribution
€ 383 750
Address
Wellington Square University Offices
OX1 2JD Oxford
Activity type
Higher or Secondary Education Establishments